Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11502128 | 0.68 | KMT2A (0.38) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL17791230 | 0.68 | ADORA2B (0.45) | ADORA2BGLABLMADORA3GAA | |
| SCHEMBL1629499 | 0.66 | ADORA2B (0.39) | ADORA2BGLABLMADORA3ADORA2A | |
| SCHEMBL11095849 | 0.66 | NPSR1 (0.40) | GLAMEN1KMT2A | |
| SCHEMBL316930 | 0.64 | ADORA2B (0.62) | ADORA2BGLABLMADORA3ADORA2A | |
| SCHEMBL11158053 | 0.62 | PTGS2 (0.32) | — | |
| SCHEMBL10656238 | 0.62 | ALDH1A1 (0.52) | ADORA2BADORA2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL10923406 | 0.62 | TP53 (0.50) | MEN1KMT2A | |
| SCHEMBL9292730 | 0.62 | ALDH1A1 (0.42) | ADORA2BGLABLMADORA3GAA | |
| SCHEMBL19147853 | 0.61 | ALDH1A1 (0.53) | ADORA2BGAAADORA2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010890-B1 | BIOORTHOGONAL METHODS AND COMPOUNDS | UNIV COURT UNIV OF EDINBURGH (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-20180362473-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | UNIV COURT UNIV OF EDINBURGH (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-3010890-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | The University Court of the University of Edinburgh (GB) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202994-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2014-12-24 | — | — | WO | disclosed |
| EP-1169309-A4 | PROPYNYL URACILS | LONZA AG (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6344460-B1 | BACTERICIDES, FUNGICIDES, AND PRESERVATIVES | LONZA INC. | 2002-02-05 | — | — | US | disclosed |
| EP-1169309-A1 | PROPYNYL URACILS | LONZA INC. (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061565-A1 | PROPYNYL URACILS | LONZA INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362473-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | ADORA2B 3282/4885GLA 985/4885BLM 2120/4885 |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | ADORA2B 3282/4885GLA 985/4885BLM 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.